PSMA PET has emerged as the preferred imaging modality for evaluating biochemical recurrence (BCR) of prostate cancer owing to its superior sensitivity and specificity compared with conventional imaging techniques such as CT, MRI, and bone scintigraphy—particularly at low PSA levels. The gene discussed is FOLH1; the disease is prostate cancer.